© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.
May 4th 2021
Criteria for diagnosis and risk stratification in patients with relapsed/refractory multiple myeloma.
Strategies for patient assessment and treatment selection in patients with relapsed/refractory multiple myeloma.
May 11th 2021
Insight regarding the risk of development of triple-class refractory disease in multiple myeloma and recommendations for working with patients to establish an appropriate treatment plan and counsel on goals of therapy.
Considerations for adding selinexor to backbone treatments for triple-class refractory multiple myeloma based on data revealed by the STOMP trial.
May 18th 2021
The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.
An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.
May 25th 2021
Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.
Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.
Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.